AOD-9604 is a modified fragment of human growth hormone, specifically the C-terminal fragment corresponding to amino acids 176-191. The name stands for Anti-Obesity Drug 9604, reflecting the research focus that motivated its development. The fragment has been modified with the addition of a tyrosine residue at the N-terminus to stabilize the peptide for research purposes.
Researchers have studied AOD-9604 for its potential interactions with fat metabolism pathways independent of full growth hormone signaling. Studies have examined how AOD-9604 may stimulate lipolysis – the breakdown of stored triglycerides – and inhibit lipogenesis – the formation of new fat cells – in adipose tissue. Preclinical research has explored its effects on beta-3 adrenergic receptors, which play a role in fat cell activity.
Animal model studies have investigated AOD-9604’s effects on body composition, particularly in rodent models of diet-induced obesity. Researchers have noted that unlike full-length GH, AOD-9604 does not appear to significantly affect blood glucose levels or IGF-1 in preclinical studies, making it a useful research tool for isolating specific aspects of GH biology related to fat metabolism.
For research use only. Not for human consumption. Iron Prairie Labs products are intended for qualified researchers and laboratory use only.
